Leerink Partnrs Issues Optimistic Forecast for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q3 2025 earnings at $0.13 EPS and FY2026 earnings at $0.48 EPS.

Several other brokerages have also weighed in on IRWD. JMP Securities decreased their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a report on Thursday, January 30th. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Leerink Partners decreased their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Finally, StockNews.com raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Price Performance

IRWD traded down $0.04 during trading hours on Monday, reaching $0.65. 2,428,559 shares of the stock traded hands, compared to its average volume of 2,526,670. The firm's fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $2.61. The company has a market cap of $105.01 million, a price-to-earnings ratio of -21.63 and a beta of 0.37. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). The firm had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $36,000. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $45,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $47,000. Envestnet Asset Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Xponance Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.